{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T10:09:29Z","timestamp":1772014169475,"version":"3.50.1"},"reference-count":44,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Department of Defense Prostate Cancer Research Program","award":["W81XWH-14-2-0183"],"award-info":[{"award-number":["W81XWH-14-2-0183"]}]},{"name":"Pacific Northwest Prostate Cancer SPORE","award":["P50CA97186"],"award-info":[{"award-number":["P50CA97186"]}]},{"name":"NIH Program","award":["PO1CA163227"],"award-info":[{"award-number":["PO1CA163227"]}]},{"name":"Sicher Family Faculty Research Grant"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background\/Objectives: Prostate cancer is the most diagnosed and third most deadly cancer among men in Europe. Metastatic castration-resistant prostate cancer (mCRPC) is incurable and resistant to standard androgen ablation therapy. More biomarkers are needed to select patients for novel personalized treatments. Previous whole-genome RNA sequencing results indicated a possible role for cluster of differentiation 24 (CD24) and neuropeptide Y (NPY) as diagnostic or prognostic biomarkers in androgen receptor-positive (AR+) mCRPC. Methods: We analyzed tissue microarrays representing 127 primary prostate cancers (with matched adjacent benign prostatic glands) and 124 metastases (from 34 patients) using immunohistochemistry to detect CD24 or NPY. Results: CD24 was more highly expressed in primary prostate cancer than in adjacent benign tissue for nuclear (p: &lt;0.001), cytoplasmic (p: &lt;0.001), and membranous staining (p: &lt;0.001), while NPY showed no difference. Average NPY scores were lower in prostate cancers that later recurred (geometric mean 17.6, 95% CI: 9.5\u201332.5) compared to those that did not (38.7, CI: 23.2\u201364.4; p: 0.044, d: 0.773). In mCRPC, CD24 was detectable in 76% of cores at the cell membrane and in 58% in the nucleus. NPY was detectable in the cytoplasm of 17%. Scores for NPY and nuclear (but not membranous) CD24 were higher in AR+ mCRPC. In the RNA sequencing results, CD24 did not correlate with AR or kallikrein-related peptidase 3 (KLK3), while NPY positively correlated with AR (rs: 0.313; p: &lt;0.004) and KLK3 (rs: 0.400; p: &lt;0.004). NPY and CD24 scores did not correlate with neuroendocrine mCRPC markers. Nuclear and membranous CD24 showed differential expression by metastatic site. Conclusions: We did not find strong evidence to support the use of CD24 or NPY alone as clinical biomarkers. Membranous and nuclear CD24 were expressed in the majority of mCRPC specimens, while NPY expression was more limited. NPY and nuclear CD24 were more highly expressed in AR+ mCRPC than AR\u2212 neuroendocrine disease, and nuclear CD24 displayed site-specific expression, suggesting a potential role for nuclear CD24 in promoting AR+ mCRPC.<\/jats:p>","DOI":"10.3390\/diagnostics16050657","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:50:27Z","timestamp":1772009427000},"page":"657","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterization and Evaluation of CD24 and NPY as Biomarkers for Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.3390","volume":"16","author":[{"given":"Peter R.","family":"McHenry","sequence":"first","affiliation":[{"name":"Department of Biology, Middle East University, Beirut 1202-2040, Lebanon"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2910-7841","authenticated-orcid":false,"given":"Najla","family":"Fakhruddin","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut 1107-2020, Lebanon"}]},{"given":"Kevin","family":"Homer","sequence":"additional","affiliation":[{"name":"Texas Pathology Consultants, Burleson, TX 76028, USA"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2151-2449","authenticated-orcid":false,"given":"Rui M.","family":"Gil da Costa","sequence":"additional","affiliation":[{"name":"Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA"}]},{"given":"Lawrence D.","family":"True","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA"}]},{"given":"Colm","family":"Morrissey","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Washington, Seattle, WA 98195, USA"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"ref_1","unstructured":"(2025, May 26). Cancer Today. World Health Organization, International Agency for Research on Cancer, Global Cancer Observatory. Available online: https:\/\/gco.iarc.who.int\/today\/en\/dataviz\/tables?mode=cancer&group_popultaions=1&multiple_populations=1&sexes=1&populations=908."},{"key":"ref_2","first-page":"742","article-title":"Resistance to Second Generation Antiandrogens in Prostate Cancer: Pathways and Mechanisms","volume":"3","author":"Verma","year":"2020","journal-title":"Cancer Drug Resist."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/21681805.2020.1739139","article-title":"Survival in Patients Diagnosed with Castration-Resistant Prostate Cancer: A Population-Based Observational Study in Sweden","volume":"54","author":"Aly","year":"2020","journal-title":"Scand. J. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1158\/1078-0432.CCR-15-0157","article-title":"SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer","volume":"21","author":"Zhang","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s12964-023-01315-w","article-title":"Targeting CD24 as a Novel Immunotherapy for Solid Cancers","volume":"21","author":"Yang","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ijc.33249","article-title":"Novel Insights into the Function of CD24: A Driving Force in Cancer","volume":"148","author":"Altevogt","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/jcp.2009.069310","article-title":"CD24 Shows Early Upregulation and Nuclear Expression but Is Not a Prognostic Marker in Colorectal Cancer","volume":"62","author":"Ahmed","year":"2009","journal-title":"J. Clin. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1186\/s12967-025-06477-4","article-title":"Nuclear CD24 Promotes IL-6 Secretion in Fibroblasts","volume":"23","author":"Sheng","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/s41388-018-0575-7","article-title":"Mutant Kras-Induced Upregulation of CD24 Enhances Prostate Cancer Stemness and Bone Metastasis","volume":"38","author":"Weng","year":"2019","journal-title":"Oncogene"},{"key":"ref_10","first-page":"1","article-title":"Neuropeptide Y: History and Overview","volume":"Volume 162","author":"Michel","year":"2004","journal-title":"Neuropeptide Y and Related Peptides. Handbook of Experimental Pharmacology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.eururo.2015.10.053","article-title":"The Proteome of Primary Prostate Cancer","volume":"69","author":"Tyanova","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1021\/pr400547s","article-title":"Plasma Low-Molecular-Weight Proteome Profiling Identified Neuropeptide-Y as a Prostate Cancer Biomarker Polypeptide","volume":"12","author":"Ueda","year":"2013","journal-title":"J. Proteome Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Tong, Y., Tan, Z., Wang, P., and Gao, X. (2023). A Machine Learning Method for Predicting Biomarkers Associated with Prostate Cancer. Front. Biosci.-Landmark, 28.","DOI":"10.31083\/j.fbl2812333"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11864-025-01317-5","article-title":"PSMA-Based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future","volume":"26","author":"Ayzman","year":"2025","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e473636","DOI":"10.1200\/EDBK-25-473636","article-title":"State of the Art: Personalizing Treatment for Patients With Metastatic Castration-Resistant Prostate Cancer","volume":"45","author":"Abida","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1172\/JCI128212","article-title":"Molecular Profiling Stratifies Diverse Phenotypes of Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer","volume":"129","author":"Labrecque","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1158\/0008-5472.CAN-21-0307","article-title":"RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer","volume":"81","author":"Labrecque","year":"2021","journal-title":"Cancer Res."},{"key":"ref_18","unstructured":"(JASP, 2025). JASP, Version 0.19.3."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1007\/s00432-022-04540-x","article-title":"Neuropeptide Y and Its Receptors in Prostate Cancer: Associations with Cancer Invasiveness and Perineural Spread","volume":"149","author":"Sigorski","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.expneurol.2016.05.018","article-title":"Lack of CAR Impacts Neuronal Function and Cerebrovascular Integrity in Vivo","volume":"283","author":"Boussadia","year":"2016","journal-title":"Exp. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1158\/0008-5472.CAN-17-0367","article-title":"Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis","volume":"77","author":"Duex","year":"2017","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"306","DOI":"10.30699\/ijp.2024.2021959.3251","article-title":"Differences in CD24 Expression Between Prostate Adenocarcinoma and Benign Prostatic Hyperplasia: A Cross-Sectional Study","volume":"19","author":"Sajedifar","year":"2024","journal-title":"Iran. J. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.euros.2024.06.008","article-title":"Neuropeptide Y and Derivates Are Not Ready for Prime Time in Prostate Cancer Early Detection","volume":"66","author":"Maurer","year":"2024","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Leis-Filho, A.F., Lainetti, P.d.F., Franzoni, M.S., Palmieri, C., Kobayshi, P.E., Laufer-Amorim, R., and Fonseca-Alves, C.E. (2021). A Comparative in Silico Analysis of CD24\u2019s Prognostic Value in Human and Canine Prostate Cancer. J. Pers. Med., 11.","DOI":"10.3390\/jpm11030232"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/pros.10324","article-title":"CD24 Expression Is a Significant Predictor of PSA Relapse and Poor Prognosis in Low Grade or Organ Confined Prostate Cancer","volume":"58","author":"Kristiansen","year":"2004","journal-title":"Prostate"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1631\/jzus.2007.B0853","article-title":"Quantitative Analysis of a Panel of Gene Expression in Prostate Cancer\u2014With Emphasis on NPY Expression Analysis","volume":"8","author":"Liu","year":"2007","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.euo.2019.05.001","article-title":"Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications","volume":"2","author":"Alshalalfa","year":"2019","journal-title":"Eur. Urol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1158\/1078-0432.CCR-18-2912","article-title":"Depression-Induced Neuropeptide Y Secretion Promotes Prostate Cancer Growth by Recruiting Myeloid Cells","volume":"25","author":"Cheng","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Sigorski, D., Gulczy\u0144ski, J., Sejda, A., Rogowski, W., and I\u017cycka-\u015awieszewska, E. (2021). Investigation of Neural Microenvironment in Prostate Cancer in Context of Neural Density, Perineural Invasion, and Neuroendocrine Profile of Tumors. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.710899"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/pros.24081","article-title":"Neuropeptide Y Nerve Paracrine Regulation of Prostate Cancer Oncogenesis and Therapy Resistance","volume":"81","author":"Ding","year":"2021","journal-title":"Prostate"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4137\/BMI.S2185","article-title":"Immunohistochemistry as an Important Tool in Biomarkers Detection and Clinical Practice","volume":"5","author":"Matos","year":"2010","journal-title":"Biomark. Insights"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-Based Map of the Human Proteome","volume":"347","author":"Fagerberg","year":"2015","journal-title":"Science"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"118117","DOI":"10.1016\/j.biopha.2025.118117","article-title":"Neuropeptide Y Receptors 1 and 2 as Molecular Targets in Prostate and Breast Cancer Therapy","volume":"187","author":"Romeo","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1021\/acs.bioconjchem.3c00313","article-title":"Development of Radiopharmaceuticals for NPY Receptor-5 (Y5) Nuclear Imaging in Tumors by Synthesis of Specific Agonists and Investigation of Their Binding Mode","volume":"34","author":"Bodin","year":"2023","journal-title":"Bioconjug. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10555-024-10237-z","article-title":"Neuropeptide Y in Cancer\u2014Biological Functions and Potential Clinical Implications","volume":"44","author":"Sigorski","year":"2025","journal-title":"Cancer Metastasis Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4864","DOI":"10.1111\/febs.16880","article-title":"CD24 Targeting with NK-CAR Immunotherapy in Testis, Prostate, Renal and (Luminal-Type) Bladder Cancer and Identification of Direct CD24 Interaction Partners","volume":"290","author":"Thomas","year":"2023","journal-title":"FEBS J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"68.e21","DOI":"10.1016\/j.urolonc.2023.12.012","article-title":"Expression of Stem Cell Markers as Predictors of Therapeutic Response in Metastatic Prostate Cancer Patients","volume":"42","author":"Nandagopal","year":"2024","journal-title":"Urol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Ghoderao, P., Kwiatkowska-Borowczyk, E., Sahare, S., and Dams-Kozlowska, H. (2025). Targeting Drug-Tolerant Persister Cancer Cells: Can Nanomaterial-Based Strategies Be Helpful for Anti-DTP Therapies?. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17111428"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Brata, R.D., Marcut, L., Barb, A.C., Manole, A., Ciolofan, A., Dumitru, C.S., Zara, F., and Patrascu, R. (2025). MicroRNAs as Emerging Therapeutic Targets Modulating the Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262110794"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Swain, A., Jena, S.R., and Samanta, L. (2025). Smart Nanocarriers for Cancer: Harnessing Exosomes and Lipid Systems in Photodynamic and Immunotherapy. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1687953"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/joim.20118","article-title":"The Pharmacotherapeutic Potential of Neuropeptide Y for Chronic Pain","volume":"298","author":"Nie","year":"2025","journal-title":"J. Intern. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1002\/cncr.34433","article-title":"Racial Disparities in Black Men with Prostate Cancer: A Literature Review","volume":"128","author":"Lillard","year":"2022","journal-title":"Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e2445505","DOI":"10.1001\/jamanetworkopen.2024.45505","article-title":"Racial and Ethnic Differences in Prostate Cancer Epidemiology Across Disease States in the VA","volume":"7","author":"Stock","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/pros.23973","article-title":"A CD24-P53 Axis Contributes to African American Prostate Cancer Disparities","volume":"80","author":"Liu","year":"2020","journal-title":"Prostate"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/5\/657\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T09:17:22Z","timestamp":1772011042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/5\/657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["diagnostics16050657"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16050657","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]}}}